necitumumab + gemcitabine + cisplatin

Necitumumab + gemcitabine + cisplatin is a combination regimen used as first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC). Necitumumab is a recombinant human IgG1 monoclonal antibody that targets the epidermal growth factor receptor (EGFR), blocking ligand binding and downstream signaling involved in tumor cell proliferation and survival. Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while cisplatin is a platinum-based chemotherapeutic agent causing DNA crosslinking and apoptosis. The addition of necitumumab to gemcitabine and cisplatin has been shown to improve overall survival in patients with advanced squamous NSCLC compared to chemotherapy alone[1][4][6].